North China Pharmaceutical Jintan Biotechnology

North China Pharmaceutical Jintan Biotechnology is a high-tech biopharmaceutical subsidiary of North China Pharmaceutical Group (NCPC), specializing in the research, development, and large-scale production of recombinant protein drugs and vaccines. Established in 1994, the company is a pioneer in China's biotechnology industry, operating advanced GMP-certified facilities for mammalian cell culture and microbial fermentation. Its core product portfolio includes recombinant human erythropoietin (EPO), recombinant human granulocyte colony-stimulating factor (G-CSF), and recombinant hepatitis B vaccines. Jintan Biotechnology serves both domestic and international markets, leveraging its integrated R&D and manufacturing capabilities to provide affordable biologic therapies. The company's manufacturing base in Shijiazhuang is one of the largest of its kind in China, supporting a robust supply chain for essential medicines. It continues to focus on therapeutic areas such as oncology, nephrology, and infectious diseases to address unmet medical needs.